Completed PHASE1/PHASE2 INTERVENTIONAL 5-arm NCT01187043

Determination of the Lowest, Safe and Effective Dose of Proellex

A Single-Blind, Placebo Run-in, Phase I/II Study Comparing Five Oral Doses of Proellex®

Sponsor: Repros Therapeutics Inc.

Interventions Proellex

Updated 6 times since 2017 Last updated: Jun 27, 2014 Started: Aug 31, 2010 Primary completion: Mar 31, 2012 Completion: Mar 31, 2012

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1/PHASE2 trial investigates Amenorrhea and is currently completed. Repros Therapeutics Inc. leads this study, which shows 6 recorded versions since 2010 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1_PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1_PHASE2
Feb 2017 — Jun 2018 [monthly]

Completed PHASE1_PHASE2

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE1_PHASE2

First recorded

Aug 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Repros Therapeutics Inc.

Data source: Repros Therapeutics Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• San Antonio, United States